Bridging the Docosahexaenoic Acid (DHA) Gap: The Effects of Omega-3 Fatty Acid Supplementation in Premature Infants

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Prematurity
Interventions
DIETARY_SUPPLEMENT

DHA oil

Therapy Group:DHA oil administered at 50 mg/d (0.18ml) as an oil emulsion enterally with feedings or by gavage tube if the infant has one.

DIETARY_SUPPLEMENT

(MCT) Control oil

Placebo Group:MCT oil administered at 0.18 ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.

Trial Locations (1)

57117

Sanford Health USD, Sioux Falls

All Listed Sponsors
collaborator

The Gerber Foundation

OTHER

lead

Sanford Health

OTHER

NCT01908907 - Bridging the Docosahexaenoic Acid (DHA) Gap: The Effects of Omega-3 Fatty Acid Supplementation in Premature Infants | Biotech Hunter | Biotech Hunter